These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2887616)

  • 1. Clinical pharmacology of famotidine: a summary.
    Chremos AN
    J Clin Gastroenterol; 1987; 9 Suppl 2():7-12. PubMed ID: 2887616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of famotidine.
    Smith JL
    Digestion; 1985; 32 Suppl 1():15-23. PubMed ID: 2866132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of famotidine in humans.
    Chremos AN
    Am J Med; 1986 Oct; 81(4B):3-7. PubMed ID: 2877572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of various dose regimens of famotidine on basal nocturnal and meal-stimulated gastric secretion.
    Ryan JR; Chremos AN; Vargas R; Mantell G; Johnson CL; McMahon FG
    Clin Pharmacol Ther; 1987 Aug; 42(2):225-31. PubMed ID: 2886245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MK-208, a novel histamine H2-receptor inhibitor with prolonged antisecretory effect.
    McCallum RW; Chremos AN; Kuljian B; Tupy-Visich MA; Huber PB
    Dig Dis Sci; 1985 Dec; 30(12):1139-44. PubMed ID: 2866073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interdigestive antroduodenal motility and gastric acid secretion.
    Gielkens HA; Nieuwenhuizen A; Biemond I; Lamers CB; Masclee AA
    Aliment Pharmacol Ther; 1998 Jan; 12(1):27-33. PubMed ID: 9692697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisecretory effects of a novel and long-lasting histamine H2-receptor antagonist, YM-14471, in rats and dogs.
    Yuki H; Kamato T; Nishida A; Fujihara A; Takeda M; Miyata K
    Jpn J Pharmacol; 1993 Nov; 63(3):345-51. PubMed ID: 7906319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.
    Lin JH
    Clin Pharmacokinet; 1991 Mar; 20(3):218-36. PubMed ID: 1673880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of the novel H2 antagonist famotidine: in vitro studies.
    Bertaccini G; Coruzzi G; Poli E; Adami M
    Agents Actions; 1986 Nov; 19(3-4):180-7. PubMed ID: 2881455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of antisecretory action of a new H2-antagonist, YM-11170, in conscious dogs.
    Takeda M; Takagi T; Maeno H
    Eur J Pharmacol; 1983 Aug; 91(4):371-6. PubMed ID: 6137398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Famotidine, a new H2-receptor antagonist. Effect on parietal, nonparietal, and pepsin secretion in man.
    Smith JL; Gamal MA; Chremos AN; Graham DY
    Dig Dis Sci; 1985 Apr; 30(4):308-12. PubMed ID: 2858363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute effects of ranitidine, famotidine and omeprazole on plasma gastrin in the rat.
    Decktor DL; Pendleton RG; Kellner AT; Davis MA
    J Pharmacol Exp Ther; 1989 Apr; 249(1):1-5. PubMed ID: 2565384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide.
    Klotz U; Arvela P; Rosenkranz B
    Eur J Clin Pharmacol; 1985; 28(6):671-5. PubMed ID: 2866097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In man histamine and muscarinergic mechanisms are essential mediators of acid secretion in response to synthetic human gastrin (1-17).
    Zimmerhackl B; Wünsch E; Classen M; Schusdziarra V; Schepp W
    Regul Pept; 1993 Jul; 46(3):583-92. PubMed ID: 8105512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a histamine H2-receptor antagonist, famotidine, on gastric secretion in healthy subjects.
    Fukuda Y; Ikezoe I; Okabayashi M; Ohama I; Shimoyama T
    Clin Ther; 1987; 9(5):528-35. PubMed ID: 2889528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
    Campoli-Richards DM; Clissold SP
    Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma famotidine concentration versus intragastric pH in patients with upper gastrointestinal bleeding and in healthy subjects.
    Echizen H; Shoda R; Umeda N; Ishizaki T
    Clin Pharmacol Ther; 1988 Dec; 44(6):690-8. PubMed ID: 2904311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological analysis of the CCKB/gastrin receptors mediating pentagastrin-stimulated gastric acid secretion in the isolated stomach of the immature rat.
    Hills DM; Gerskowitch VP; Roberts SP; Welsh NJ; Shankley NP; Black JW
    Br J Pharmacol; 1996 Dec; 119(7):1401-10. PubMed ID: 8968549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of effects of oral and intravenous famotidine on inhibition of nocturnal gastric acid secretion.
    Ryan JR; Vargas R; McMahon FG; Chremos AN
    Am J Med; 1986 Oct; 81(4B):60-4. PubMed ID: 2877576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of Famotidine in gastric acidity, plasma secretin and gastrin in duodenal ulcer patients. With reference to 24-hour intragastric pH monitoring].
    Shiratori K; Watanabe S; Maruyama M; Itoh Y; Adachi H; Kurokawa K; Takeuchi T
    Nihon Shokakibyo Gakkai Zasshi; 1984 Mar; 81(3):855-63. PubMed ID: 6146733
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.